$0.46
+0.61%Xtant Medical Holdings, Inc. develops, manufactures, and markets regenerative medicine products and medical devices for orthopedic and neurological surgeons in the United States and internationally. Its biomaterial products include OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSponge SC that fills bony defects in the subchondral region of joints; OsteoSelect DBM Putty for osteoinductive bone growth; OsteoSelect PLUS DBM Putty for use as a bone void filler and bone graft substitute in the pelvis, extremities, and posterolateral spine; OsteoFactor, which contains various proteins and peptides that support bone formation and remodeling; OsteoWrap; and OsteoVive Plus, a growth factor enriched cellular bone matrix. The company also provides 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone. In addition, it processes and distributes sports allografts for anterior and posterior cruciate ligament repairs, anterior cruciate ligament reconstruction, and meniscal repair; milled spinal allografts for cortical bone milled to desired shapes and dimensions; and traditional allografts for orthopedics, neurology, podiatry, oral/maxillofacial, genitourinary, and plastic/reconstructive applications. Further, the company offers Certex spinal fixation, Spider cervical plating, Axle interspinous fusion, Silex Sacroiliac joint fusion, Xpress minimally invasive pedicle screw, and Fortex Pedicle screw systems. Additionally, it provides Calix for cervical and thoracolumbar applications, Axle-X interspinous fusion system, Irix-C cervical integrated fusion system, and Irix-A Lumbar integrated fusion system. The company was formerly known as Bacterin International Holdings, Inc. and changed its name to Xtant Medical Holdings, Inc. in July 2015. Xtant Medical Holdings, Inc. is headquartered in Belgrade, Montana.
Chief Financial Officer
Compensation
$444,956
Chief Operations Officer
Compensation
$450,492
President, Chief Executive Officer & Director
Compensation
$654,604
Vice President of Human Resources
During the last 12 months, there has been no insider trading activity reported for XTNT.
0
0.00
0
0.00
+0
+$0
0
0.00
0
0.00
+0
+$0
0
0.00
0
0.00
+0
+$0
0
0.00
0
0.00
+0
+$0
No buying activity
No selling activity
No insider trading activity reported. This could indicate blackout periods, lack of conviction, or regulatory restrictions.
No insider trading activity reported from any insiders in the past year.
XTNT - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2025 N/A | September 15, 2025 | September 15, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | June 10, 2024 | June 10, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | June 08, 2023 | June 07, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | September 20, 2022 | September 20, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | June 14, 2021 | June 14, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | September 10, 2020 | September 10, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | September 20, 2019 | September 20, 2019 | 2019 | |
DEF 14A DEF 14A 2018 N/A | June 26, 2018 | June 26, 2018 | 2018 | |
DEF 14A DEF 14A 2018 N/A | January 22, 2018 | February 13, 2018 | 2018 | |
DEF 14A DEF 14A 2017 N/A | December 08, 2017 | December 29, 2017 | 2017 |
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.